Eledon Pharmaceuticals, Inc. (ELDN) News
Follow Eledon Pharmaceuticals, Inc. (ELDN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: Tegoprubart 24—month kidney benefit and FDA fast—track, +13%
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) saw shares surge after the FDA granted fast-track status to tegoprubart following Phase 2 results showing significantly better kidney function through 24 months versus tacrolimu
REGULATION | Sep 28, 2026, 11:07 AM UTC
M
Eledon shares jump after FDA fast-track designation for kidney treatment
Eledon Pharmaceuticals said the Food and Drug Administration granted fast-track designation for its kidney treatment. The stock rose 13% to $3.04 on Tuesday and is up 87% this year.
REGULATION | Sep 22, 2026, 04:06 PM UTC
H
ELDN - Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
ELDN - Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
GEOPOLITICS | Sep 22, 2026, 11:00 AM UTC
L
Eledon to present tegoprubart kidney-transplant rejection safety, efficacy
Eledon Pharmaceuticals said an oral presentation will cover long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection at the upcoming International Congress of The Transplantation Society.
GEOPOLITICS | Sep 09, 2026, 11:04 AM UTC
L
Eledon Pharmaceuticals to present at Transplantation Society congress
Eledon Pharmaceuticals announced it will present at the International Congress of The Transplantation Society.
GEOPOLITICS | Sep 09, 2026, 11:00 AM UTC
M
Eledon submits tegoprubart islet transplantation IND; first patients enrolled
Eledon Pharmaceuticals submitted an IND to the FDA for an Eledon-sponsored registrational tegoprubart islet cell transplantation study for type 1 diabetes. It also enrolled first patients in a new investigator-initiated
REGULATION | Sep 03, 2026, 11:08 AM UTC
L
Eledon Pharmaceuticals reports Q2 2026 financial results
Eledon Pharmaceuticals (ELDN) reports second-quarter 2026 financial results and recent business highlights.
EARNINGS | Aug 13, 2026, 08:09 PM UTC
L
ELDN new Buy W/ $12 PT @ Rodman
ELDN new Buy W/ $12 PT @ Rodman
EQUITY | Jul 21, 2026, 12:32 PM UTC
L
ELDN Initiated Buy W/$12.00 PT at Rodman & Renshaw
ELDN Initiated Buy W/$12.00 PT at Rodman & Renshaw
EQUITY | Jul 21, 2026, 12:09 PM UTC
L
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ: ELDN ) anti-CD40L antibody, tegoprubart, an
REGULATION | Jul 01, 2026, 01:33 PM UTC
M
ELDN: Presents Kidney Transplant Data
Eledon Pharma presents new long-term data from Phase 2 BESTOW clinical program evaluating Tegoprubart in patients undergoing kidney transplantation at ATC 2026
EQUITY | Jun 22, 2026, 11:20 AM UTC
M
ELDN Presents BESTOW Results
Eledon presents long-term extension phase 2 BESTOW results showing sustained higher kidney function and improved patient-reported outcomes with Tegoprubart compared with Tacrolimus
EQUITY | Jun 22, 2026, 11:01 AM UTC